Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARCT Arcturus Therapeutics Ltd.

Post-Market Trading 01-08 19:56:28 EST

18.95

-1.88

-9.03%

盘后20.01

+1.06+5.59%

18:44 EST

High20.94	Low18.71	Vol326.47K
Open20.59	D1 Closing20.83	Amplitude10.71%
Mkt Cap513.31M	Tradable Cap469.98M	Total Shares27.09M
T/O6.29M	T/O Rate1.32%	Tradable Shares24.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ARCT","market":"US","secType":"STK","nameCN":"Arcturus Therapeutics Ltd.","latestPrice":18.95,"timestamp":1736370000000,"preClose":20.83,"halted":0,"volume":326467,"hourTrading":{"tag":"盘后","latestPrice":20.01,"preClose":18.95,"latestTime":"18:44 EST","volume":2421,"amount":45803.569617,"timestamp":1736379895461},"delay":0,"floatShares":24801158,"shares":27087359,"eps":-2.329253,"marketStatus":"Post-Market Trading","change":-1.88,"latestTime":"01-08 19:56:28 EST","open":20.59,"high":20.94,"low":18.71,"amount":6291722.952852,"amplitude":0.107057,"askPrice":22.54,"askSize":100,"bidPrice":18.99,"bidSize":70,"shortable":0,"etf":0,"ttmEps":-2.329253,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1736384400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":20.83,"preHourTrading":{"tag":"盘前","latestPrice":21.1878,"preClose":20.83,"latestTime":"09:08 EST","volume":421,"amount":8835.646563999999,"timestamp":1736345335363},"postHourTrading":{"tag":"盘后","latestPrice":20.01,"preClose":18.95,"latestTime":"18:44 EST","volume":2421,"amount":45803.569617,"timestamp":1736379895461},"volumeRatio":0.675781,"impliedVol":0.7787,"impliedVolPercentile":0.4722},"requestUrl":"/m/hq/s/ARCT/tweets","defaultTab":"tweets","newsList":[{"id":"2501877436","title":"Arcturus Therapeutics (ARCT) Initiated with a Buy at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2501877436","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501877436?lang=en_us&edition=fundamental","pubTime":"2025-01-08 23:55","pubTimestamp":1736351752,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Yasmeen Rahimi from Piper Sandler initiated coverage with a Buy rating on Arcturus Therapeutics (ARCT – Research Re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/arcturus-therapeutics-arct-initiated-with-a-buy-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/arcturus-therapeutics-arct-initiated-with-a-buy-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2501784874","title":"Vaccine Stocks Surge: Moderna Jumps 11% as COVID-19 and Flu Fears Reignite Immunization Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2501784874","media":"GuruFocus.com","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501784874?lang=en_us&edition=fundamental","pubTime":"2025-01-08 00:26","pubTimestamp":1736267193,"startTime":"0","endTime":"0","summary":"Tuesday saw bumps in Moderna , Novavax , and other vaccine producers as worries about rising COVID-19 and flu infections in the United States drove demand for immunization-oriented businesses to continue growing.Moderna rose 11%; Novavax and others, including Inovio Pharmaceuticals , CureVac , and Arcturus Therapeutics , also traded significantly higher. Manufacturers of the COVID-19 vaccination Comirnaty, Pfizer  and BioNTech , noted more meager increases.GuruFocus has detected 6 Warning Signs with MRNA.Based on last week's U.S. Centers for Disease Control and Prevention  data showing increasing COVID-19 activity in most areas and a concurrent rise in seasonal flu, especially among small children, the rally followed last week's Citing their success in lowering serious disease and hospitalization, the CDC advised Americans to get recommended vaccinations.The organization also underlined how common respiratory syncytial virus  is in young children. With its mREVIA medicine, Moderna has ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vaccine-stocks-surge-moderna-jumps-162633280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","BK4532",".IXIC","BK4585","LU1066051498.USD","MNQmain","MRNA","SG9999001176.USD","SG9999013999.USD","BK4588","BK4139","BK4551","ARCT","BK4599","LU0122379950.USD","SG9999002224.SGD","LU0225771236.USD","PFE","IE00B19Z3B42.SGD","USJW.SI","BK4581","CVAC","LU0170899867.USD","LU0306807586.USD","LU1894683264.USD","NVIW.SI","BK4007","IE00BLSP4452.SGD","LU0456855351.SGD","NVAX","SGXZ57979304.SGD","LU0868494617.USD","BK4548","LU1883839398.USD","TSYW.SI","LU1894683348.USD","PSQ","BK4583","INO","LU0058720904.USD","CDC","BNTX","BK4501","NQmain","QID","TQQQ","QLD","SQQQ","LU0234572021.USD"],"gpt_icon":1},{"id":"2501627215","title":"Arcturus Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2501627215","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501627215?lang=en_us&edition=fundamental","pubTime":"2025-01-07 19:37","pubTimestamp":1736249820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARCT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 07, 2025 06:37 ET (11:37 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","LENZ"],"gpt_icon":0},{"id":"2501318260","title":"Arcturus Starts Dosing in Phase 2 Cystic Fibrosis, Ornithine Transcarbamylase Deficiency Treatment Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2501318260","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501318260?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:26","pubTimestamp":1736198772,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics  said Monday it started dosing patients with cystic fibrosis and ornithine transcarbamylase deficiency in phase 2 multiple ascending dose studies in December 2024.Patients in the phase 2 cystic fibrosis study are expected to get daily treatments of ARCT-032 over a 28-day period, according to the company.Patients with ornithine transcarbamylase deficiency will receive five intravenous infusions of ARCT-810 over two months and the first participant in the US received 0.5 milligrams per kilogram dose in December.The company expects phase 2 interim data for both program in H1.Arcturus shares were up more than 6% in regular trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2501671062","title":"BRIEF-Arcturus Therapeutics Announces Initiation Of Dosing In Phase 2 Multiple Ascending Dose Studies For Cystic Fibrosis And Ornithine Transcarbamylase Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2501671062","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501671062?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:14","pubTimestamp":1736198050,"startTime":"0","endTime":"0","summary":"BRIEF-Arcturus Therapeutics Announces Initiation Of Dosing In Phase 2 Multiple Ascending Dose Studies For Cystic Fibrosis And Ornithine Transcarbamylase DeficiencyJan 6 (Reuters) - Arcturus Therapeuti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3O21KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2501288267","title":"Arcturus initiates dosing in Phase 2 studies for CF and OTC deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2501288267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501288267?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:05","pubTimestamp":1736197520,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics (ARCT) Holdings announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcturus-initiates-dosing-in-phase-2-studies-for-cf-and-otc-deficiency?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcturus-initiates-dosing-in-phase-2-studies-for-cf-and-otc-deficiency?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","CF","BK4588","BK4093","ARCT","BK4139"],"gpt_icon":0},{"id":"2501815267","title":"Arcturus Therapeutics Holdings Inc -Phase 2 Interim Data for Both Mrna Therapeutic Programs on Track for First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501815267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501815267?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:01","pubTimestamp":1736197266,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3O21KV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2501267813","title":"Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (Otc) Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2501267813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501267813?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:01","pubTimestamp":1736197266,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3O21KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2501948062","title":"Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2501948062","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501948062?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:01","pubTimestamp":1736197260,"startTime":"0","endTime":"0","summary":"First participants initiated Phase 2 dosing for both CF and OTC deficiency in December 2024. Phase 2 interim data for both mRNA therapeutic programs on track for first half of 2025. SAN DIEGO, January 06, 2025----Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the Company’s Phase 2 multiple ascending dose studies.Each participant in the Phase 2 CF study  is expected to receive daily treatments of ARCT-032 over a period of 28 days.ARCT-032 is an inhaled investigational mRNA therapeutic designed to express normal functional CFTR in the lungs of individuals with CF. ARCT-032 has received Orphan Medicinal Product Designation from the European Medicines Agency  and Orphan Drug Designation along with Rare Pediatric Disease Designation fr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-announces-initiation-dosing-210100304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LENZ","BK4585","BK4093","PIP","RNA","ARCT","BK4505","CF","BK4139"],"gpt_icon":1},{"id":"2494372770","title":"High Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2494372770","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494372770?lang=en_us&edition=fundamental","pubTime":"2024-12-25 02:02","pubTimestamp":1735063363,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has experienced a 2.2% drop, yet it is up 24% over the past year with earnings forecast to grow by 15% annually. In this context of fluctuating yet promising growth, identifying high-growth tech stocks such as Arcturus Therapeutics Holdings requires an understanding of their potential to capitalize on technological advancements and market opportunities amidst these dynamic conditions.Top 10 High Growth Tech Companies In The United States. Click to explore a detailed breakdown of our findings in Arcturus Therapeutics Holdings' health report.Review our historical performance report to gain insights into Arcturus Therapeutics Holdings''s past performance.Overview: Rapid7, Inc. offers cybersecurity solutions through its Rapid7, Nexpose, and Metasploit brands and has a market c","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/._HFmWFPcwt6muyT_tZE7g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b394072c431426666ba19d9f9857f297","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/._HFmWFPcwt6muyT_tZE7g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b394072c431426666ba19d9f9857f297"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-including-180243710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2045819591.USD","IE00BF5LJ272.USD","RPD","LENZ","BK4139","GLOB","IE00B0169N27.USD","LU2125910500.SGD","ARCT","BK4134"],"gpt_icon":0},{"id":"2492541158","title":"We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2492541158","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492541158?lang=en_us&edition=fundamental","pubTime":"2024-12-20 19:34","pubTimestamp":1734694462,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.So, the natural question for Arcturus Therapeutics Holdings  shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn.View our latest analysis for Arcturus Therapeutics Holdings. Arcturus Therapeutics Holdings has a market capitalisation of US$401m and burnt through US$62m last year, which is 15% of the company's market value. As a result, we'd","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-not-very-worried-arcturus-113422246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI",".IXIC","BK4585","LU2210149790.SGD","MNQmain","BK4588","BK4139","ARCT","LU2095319765.USD","IE00BKPKM429.USD","USJW.SI","NVIW.SI","NDAQ","SQQQ","TSYW.SI","PSQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112","NQmain","QID","TQQQ","QLD","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2492692497","title":"Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492692497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492692497?lang=en_us&edition=fundamental","pubTime":"2024-12-18 13:50","pubTimestamp":1734501010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report) and M...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arcturus-therapeutics-arct-and-madrigal-pharmaceuticals-mdgl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arcturus-therapeutics-arct-and-madrigal-pharmaceuticals-mdgl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARCT","BK4588","BK4137","BK4585","MDGL","BK4139","HCSG"],"gpt_icon":0},{"id":"2490486016","title":"Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2490486016","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490486016?lang=en_us&edition=fundamental","pubTime":"2024-12-12 00:55","pubTimestamp":1733936108,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc.  stands against other worst ARK stocks to buy according to short sellers.Cathie Wood ofARK Investmentis one of Wall Street’s most well-known hedge fund bosses. In a hedge fund industry dominated by players that focus on quantitative trading, value stocks, and balanced portfolios, Wood stands out from the pack by focusing on disruptive innovation and firms that she and her firm believe will change the world.At the heart of Ark Invest’s trading strategy is the fund’s flagship ARK Innovation ETF fund. Over the past five years, this fund has gained a modest 23% which is substantially lower than the flagship S&P index’s 93.5%. Zooming into its 2024 performance, this fund has gained 20.5% while the index is up by 28.3%.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5wptGPpITOozMDVUNSZx9Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d27550770a7f77135d3a5312616d88a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5wptGPpITOozMDVUNSZx9Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d27550770a7f77135d3a5312616d88a0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-arcturus-therapeutics-arct-worst-165508619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","QLD","BK4139","BK4588","QID","ARKK","BK4544","NQmain","TQQQ","BK4585","MNQmain","PSQ",".IXIC","ARCT"],"gpt_icon":1},{"id":"2486834298","title":"Arcturus Therapeutics to Attend Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2486834298","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486834298?lang=en_us&edition=fundamental","pubTime":"2024-11-27 05:01","pubTimestamp":1732654860,"startTime":"0","endTime":"0","summary":"SAN DIEGO, November 26, 2024----Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:. Webcast links can be found under Investor Relations/Events section of Arcturus’ website.Arcturus Therapeutics Public Relations & Investor RelationsNeda SafarzadehVP, Head of IR/PR/Marketing 900-2682IR@ArcturusRx.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5hl.D4MLnMOD1sOo855LHw--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/d3d6d783d9dbc0ba3096aa4405dbfebd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5hl.D4MLnMOD1sOo855LHw--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/d3d6d783d9dbc0ba3096aa4405dbfebd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-attend-upcoming-investor-210100323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LENZ","BK4585","BK4093","RNA","ARCT","BK4505","CF","BK4139"],"gpt_icon":0},{"id":"2484322639","title":"Arcturus Therapeutics to Present at Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2484322639","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484322639?lang=en_us&edition=fundamental","pubTime":"2024-11-19 09:00","pubTimestamp":1731978000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, November 19, 2024----Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT.Arcturus TherapeuticsPublic Relations & Investor RelationsNeda SafarzadehVP, Head of Investor Relations/PR & Marketing 900-2682IR@ArcturusRx.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ayEV.42liLzOxEkKDS7rkQ--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/5d70676411f8e76fdafb7bfbe3001f8f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ayEV.42liLzOxEkKDS7rkQ--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/5d70676411f8e76fdafb7bfbe3001f8f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-present-jefferies-london-010000794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","BK4585","CF","BK4588","LENZ","RNA","BK4505","HCSG","BK4093","ARCT","BK4139"],"gpt_icon":0},{"id":"2483819575","title":"Meiji Seika Pharma Announces Investment in Arcalis, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483819575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483819575?lang=en_us&edition=fundamental","pubTime":"2024-11-14 14:00","pubTimestamp":1731564001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA6SGVYS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2483848308","title":"Meiji Seika Pharma Announces Investment in ARCALIS, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483848308","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483848308?lang=en_us&edition=fundamental","pubTime":"2024-11-14 14:00","pubTimestamp":1731564000,"startTime":"0","endTime":"0","summary":"TOKYO, November 14, 2024----Meiji Seika Pharma Co., Ltd.  today announced its investment in ARCALIS, Inc. .ARCALIS is a joint venture between Axcelead, Inc., which manages a group of world-class pharmaceutical and healthcare platform companies, and Arcturus Therapeutics, Inc. a commercial mRNA medicines and vaccines company. ARCALIS is engaged in the development of mRNA pharmaceuticals and vaccines, as well as contract development and manufacturing organization  services. The company plans to establish a comprehensive system for the domestic production of mRNA vaccines, ranging from the development of manufacturing technologies to the production of both active pharmaceutical ingredients and formulations.In response to the lessons learned from the delays experienced in the development of COVID-19 vaccines during the pandemic, ARCALIS and Meiji Seika Pharma are committed to advancing the development, production, and supply of mRNA vaccines in line with the \"Strategy for Strengthening Vac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meiji-seika-pharma-announces-investment-060000101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDMO","BK4139","ARCT"],"gpt_icon":0},{"id":"2482949764","title":"Arcturus Therapeutics Gets FDA Greenlight for H5N1 Pandemic Flu Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482949764","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482949764?lang=en_us&edition=fundamental","pubTime":"2024-11-12 06:19","pubTimestamp":1731363556,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics  said late Monday the US Food and Drug Administration has given the clearance to begin the clinical study for its H5N1 pandemic flu vaccine candidate ARCT-2304.The company said the trial, which is funded by the Biomedical Advanced Research and Development Authority, is designed to enroll around 200 healthy adults in the US.The phase 1 trial aims to evaluate the safety, reactogenicity, and immunogenicity of the \"self-amplifying\" mRNA vaccine, Arctus said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","ARCT"],"gpt_icon":0},{"id":"2482976564","title":"BRIEF-Arcturus Therapeutics Receives Clearance From FDA To Begin H5N1 Pandemic Flu Vaccine Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482976564","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482976564?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:10","pubTimestamp":1731359453,"startTime":"0","endTime":"0","summary":"Nov 11  - Arcturus Therapeutics Holdings Inc :   * ARCTURUS THERAPEUTICS RECEIVES CLEARANCE FROM FDA TO BEGIN H5N1 PANDEMIC FLU VACCINE CLINICAL TRIAL   * ARCTURUS THERAPEUTICS HOLDINGS INC - STUDY TO ENROLL APPROXIMATELY 200 HEALTHY ADULTS IN U.S.Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ARCT","BK4139"],"gpt_icon":0},{"id":"2482655747","title":"Arcturus Therapeutics receives FDA clearance to begin H5N1 vaccine trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482655747","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482655747?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:05","pubTimestamp":1731359114,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics (ARCT) Holdings announced that the U.S. Food and Drug Administration has issued a “Study Can Proceed” notification for the Co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-receives-fda-clearance-to-begin-h5n1-vaccine-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-receives-fda-clearance-to-begin-h5n1-vaccine-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","ARCT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcturusrx.com","stockEarnings":[{"period":"1week","weight":0.2275},{"period":"1month","weight":0.0911},{"period":"3month","weight":-0.0484},{"period":"6month","weight":-0.1233},{"period":"1year","weight":-0.362},{"period":"ytd","weight":0.2275}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":-0.0316},{"period":"3month","weight":0.0199},{"period":"6month","weight":0.0578},{"period":"1year","weight":0.2403},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.092409},{"month":2,"riseRate":0.545455,"avgChangeRate":0.011691},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.021161},{"month":4,"riseRate":0.545455,"avgChangeRate":0.101832},{"month":5,"riseRate":0.636364,"avgChangeRate":0.1056},{"month":6,"riseRate":0.583333,"avgChangeRate":0.023074},{"month":7,"riseRate":0.583333,"avgChangeRate":0.109538},{"month":8,"riseRate":0.5,"avgChangeRate":0.045801},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.063785},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.046065},{"month":11,"riseRate":0.666667,"avgChangeRate":0.063018},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.062042}],"exchange":"NASDAQ","name":"Arcturus Therapeutics Ltd.","nameEN":"Arcturus Therapeutics Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcturus Therapeutics Ltd.,ARCT,Arcturus Therapeutics Ltd.股票,Arcturus Therapeutics Ltd.股票老虎,Arcturus Therapeutics Ltd.股票老虎国际,Arcturus Therapeutics Ltd.行情,Arcturus Therapeutics Ltd.股票行情,Arcturus Therapeutics Ltd.股价,Arcturus Therapeutics Ltd.股市,Arcturus Therapeutics Ltd.股票价格,Arcturus Therapeutics Ltd.股票交易,Arcturus Therapeutics Ltd.股票购买,Arcturus Therapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}